Buy Dabur With Target Of Rs 107

Buy Dabur With Target Of Rs 107Technical analyst Salil Sharma has maintained 'buy' rating on Dabur India Limited stock with a target of Rs 107.

According to analyst, the stock can be purchased with a stop loss of Rs 96.

The stock of the company, on Dec 02, closed at Rs 99.95 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 112.35 and a low of Rs 77.50 on BSE.

Current EPS & P/E ratio stood at 3.10 and 31.82 respectively.

Dabur India has made entry into the vitamins, minerals and supplements family after introducing Dabur NUTRiGO, which is a daily health supplement with offerings for males as well as females.

The introduction of NUTRiGO is part of Dabur's aggressive plan to augment its leadership position in the health care msection in the country, where the company currently runs with customary ayurvedic items such as Dabur Chyawanprash.

Mr. Praveen Jaipuriar, Dabur India Category Head-Health Supplements stated, "The OTC Health care segment is estimated at Rs 15,000 crores and has been identified as a key focus area for Dabur, going forward, and the launch of brand Dabur NUTRiGO is part of a series of new initiatives being rolled out by Dabur. With our long experience and expertise of operating in the health domain, we aim to establish the brand as a credible leading player in the Rs 750 crores Branded OTC Supplements category in days to come."

Mr. K K Rajesh, Dabur India Executive, Vice-President-Marketing, "Dabur has been a player in the traditional over the counter (OTC) space, with offerings like Dabur Chyawanprash and Pudin Hara over the years. The move into modern OTC healthcare therefore comes as a logical next step for us, as a part of our strategic intent in health care, given the evolving consumer and market context within health care."




Check out More news from Recruitment News :: Admissions :: Exam Results :: Telecom Sector :: Pharmaceutical Sector :: Auto Sector :: Infrastructure :: Real Estate